A Phase 2 Study of TRS005 in Patients With CD20-positive R/R DLBCL.

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

139

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

January 31, 2027

Study Completion Date

September 30, 2027

Conditions

CD20-positive Diffuse Large B-Cell Lymphoma

Interventions

DRUG

TRS005

Recombinant anti-CD20 monoclonal antibody-MMAE conjugte for injection. To be used under medical supervision.

Trial Locations (1)

Chinese Academy of Medical Sciences, Cancer Hospital, Beijing

All Listed Sponsors

lead

Zhejiang Teruisi Pharmaceutical Inc.

INDUSTRY

NCT06886139 - A Phase 2 Study of TRS005 in Patients With CD20-positive R/R DLBCL. | Biotech Hunter | Biotech Hunter